Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ciclosporin ophthalmic - Novaliq

Next Previous
Drug Profile

Ciclosporin ophthalmic - Novaliq

Alternative Names: 0.1% cyclosporin A; CyclASol 0.1%; Cyclosol; Cyclosporine; Cyclosporine-A; SHR-8028; Vevizye; VEVYE

Latest Information Update: 07 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novaliq
  • Developer Jiangsu Hengrui Medicine Co.; Novaliq
  • Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Heart failure therapies; Neuroprotectants
  • Mechanism of Action Calcineurin inhibitors; Immunomodulators; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Dry eyes
  • Research Hypersensitivity

Most Recent Events

  • 02 Oct 2024 Laboratoires Thea acquires the rights to commercialize ciclosporin in the European Union and selected countries in the Middle East and North Africa from Novaliq
  • 19 Sep 2024 Registered for Dry eyes in Iceland, Norway, Liechtenstein, European Union (Ophthalmic)
  • 31 Jul 2024 European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommends approval of Ciclosporin ophthalmic for Dry eyes (Ophthalmic, Drops) in European Union

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top